Biotech investing can be tricky. Often, the drugs that these fledgling companies produce don’t pan out, and shareholders take ...

Recursion Pharmaceuticals (NASDAQ:RXRX) is a biotech innovator who knows what ... to make a small, strategic investment in the firm back in 2023. But just because Nvidia and Cathie Wood have ...

AbbVie ( ABBV 0.64%) is a leader in biopharmaceuticals with a product portfolio spanning multiple therapeutic areas, ...

Chicago Partners Investment Group LLC boosted its position in iShares Biotechnology ETF (NASDAQ:IBB – Free Report) by 2.5% in the fourth quarter, according to its most recent Form 13F filing ...

Aurion Biotech, Inc. plans $100M IPO for corneal disease treatments, limited competition, Phase 1/2 trials underway with ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Analyst opinions on Xencor's prospects are mixed, reflecting the inherent uncertainties in biotechnology investing. Recent InvestingPro data shows that 4 analysts have revised their earnings ...

Breakthrough, a joint venture of global developer Tishman Speyer and biotechnology investment firm Bellco Capital, purchased MUSE for $159 million. MUSE consists of three buildings totaling ...

(MENAFN- PR Newswire) Breakthrough, a joint venture of global developer Tishman Speyer and biotechnology investment firm Bellco Capital, purchased MUSE for $159 million. MUSE consists of three ...

Amid the federal funding uncertainty for health and sciences, local life science leaders say this could be a moment for industry partners, investors and others to step up and support the sector.

Analyst opinions on Xencor's prospects are mixed, reflecting the inherent uncertainties in biotechnology investing. Recent InvestingPro data shows that 4 analysts have revised their earnings upwards ...